Department of Emergency Medicine, University of British Columbia, Vancouver, Canada.
British Columbia Drug and Poison Information Centre, British Columbia Centre for Disease Control, Vancouver, Canada.
Clin Toxicol (Phila). 2021 Jan;59(1):38-46. doi: 10.1080/15563650.2020.1758325. Epub 2020 May 13.
When managing opioid overdose (OD) patients, the optimal naloxone regimen should rapidly reverse respiratory depression while avoiding opioid withdrawal. Published naloxone administration guidelines have not been empirically validated and most were developed before fentanyl OD was common. In this study, rates of opioid withdrawal symptoms (OW) and reversal of opioid toxicity in patients treated with two naloxone dosing regimens were evaluated.
In this retrospective matched cohort study, health records of patients who experienced an opioid OD treated in two urban emergency departments (ED) during an ongoing fentanyl OD epidemic were reviewed. Definitions for OW and opioid reversal were developed . Low dose naloxone (LDN; ≤0.15 mg) and high dose naloxone (HDN; >0.15 mg) patients were matched in a 1:4 ratio based upon initial respiratory rate (RR). The proportion of patients who developed OW and who met reversal criteria were compared between those treated initially with LDN or HDN. Odds ratios (OR) for OW and opioid reversal were obtained logistic regression stratified by matched sets and adjusted for age, sex, pre-naloxone GCS, and presence of non-opioid drugs or alcohol.
Eighty LDN patients were matched with 299 HDN patients. After adjustment, HDN patients were more likely than LDN patients to have OW after initial dose (OR = 8.43; 95%CI: 1.96, 36.3; = 0.004) and after any dose (OR = 2.56; 95%CI: 1.17, 5.60; = 0.019). HDN patients were more likely to meet reversal criteria after initial dose (OR = 2.73; 95%CI: 1.19, 6.26; = 0.018) and after any dose (OR = 6.07; 95%CI: 1.81, 20.3; = 0.003).
HDN patients were more likely to have OW but also more likely to meet reversal criteria versus LDN patients.
在治疗阿片类药物过量(OD)患者时,理想的纳洛酮治疗方案应能迅速逆转呼吸抑制,同时避免阿片类药物戒断。已发表的纳洛酮给药指南未经实证验证,且大多数是在芬太尼 OD 较为常见之前制定的。本研究评估了两种纳洛酮给药方案治疗患者的阿片类药物戒断症状(OW)发生率和阿片类药物毒性逆转情况。
本回顾性匹配队列研究回顾了在芬太尼 OD 流行期间,两家城市急诊科(ED)治疗的阿片类药物 OD 患者的健康记录。制定了 OW 和阿片类药物逆转的定义。低剂量纳洛酮(LDN;≤0.15mg)和高剂量纳洛酮(HDN;>0.15mg)患者根据初始呼吸频率(RR)以 1:4 的比例进行匹配。比较了初始给予 LDN 或 HDN 治疗的患者中出现 OW 和符合逆转标准的患者比例。采用逻辑回归分层匹配集,并根据年龄、性别、纳洛酮前 GCS 和是否存在非阿片类药物或酒精,对 OW 和阿片类药物逆转的比值比(OR)进行调整。
80 名 LDN 患者与 299 名 HDN 患者相匹配。调整后,与 LDN 患者相比,HDN 患者初始剂量后(OR=8.43;95%CI:1.96,36.3; = 0.004)和任何剂量后(OR=2.56;95%CI:1.17,5.60; = 0.019)发生 OW 的可能性更高。HDN 患者初始剂量后(OR=2.73;95%CI:1.19,6.26; = 0.018)和任何剂量后(OR=6.07;95%CI:1.81,20.3; = 0.003)更有可能符合逆转标准。
与 LDN 患者相比,HDN 患者发生 OW 的可能性更高,但也更有可能符合逆转标准。